<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lin L</submitter><funding>Guangdong Traditional Chinese Medicine Special Fund</funding><funding>Science and Technology Program of Dongguan</funding><funding>Natural Science Foundation of Guangdong Province</funding><funding>National Natural Science Foundation of China</funding><funding>the Key Project of the National Natural Science Foundation of China</funding><pagination>26</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12798018</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(1)</volume><pubmed_abstract>Ulcerative colitis (UC) is characterised by chronic intestinal inflammation and its global prevalence is increasing. Although a variety of drugs have been approved for the clinical treatment of UC, their application is often limited by unsatisfactory long-term effects, side effects, and high treatment costs. Therefore, there is an urgent need for the development of effective drugs with fewer side effects. In this study, we found that the extracellular vesicles extracted and purified from rhizomes of Kaempferia galanga L. (KGEVs) exhibit promising therapeutic effects in treating UC disease. With an average diameter of 133.8 nm, KGEVs are rich in functional components, including lipids, proteins, and pharmacologically and immunologically active molecules. In vivo experiments revealed that KG</pubmed_abstract><journal>Journal of nanobiotechnology</journal><pubmed_title>Extracellular vesicles derived from Kaempferia Galanga L. show promise for targeted oral therapy in the treatment of ulcerative colitis.</pubmed_title><pmcid>PMC12798018</pmcid><funding_grant_id>2023A1515110757</funding_grant_id><funding_grant_id>20231800913372</funding_grant_id><funding_grant_id>20221260</funding_grant_id><funding_grant_id>82405279</funding_grant_id><funding_grant_id>2023A1515010720</funding_grant_id><funding_grant_id>81830117</funding_grant_id><pubmed_authors>Zheng Z</pubmed_authors><pubmed_authors>Gong S</pubmed_authors><pubmed_authors>Wu C</pubmed_authors><pubmed_authors>Shen C</pubmed_authors><pubmed_authors>Zhou X</pubmed_authors><pubmed_authors>Zhao X</pubmed_authors><pubmed_authors>Jiang Z</pubmed_authors><pubmed_authors>Li S</pubmed_authors><pubmed_authors>He Z</pubmed_authors><pubmed_authors>Kwan HY</pubmed_authors><pubmed_authors>Peng B</pubmed_authors><pubmed_authors>Fang W</pubmed_authors><pubmed_authors>Ma J</pubmed_authors><pubmed_authors>Jiang C</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Lin L</pubmed_authors><pubmed_authors>Zhong L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Extracellular vesicles derived from Kaempferia Galanga L. show promise for targeted oral therapy in the treatment of ulcerative colitis.</name><description>Ulcerative colitis (UC) is characterised by chronic intestinal inflammation and its global prevalence is increasing. Although a variety of drugs have been approved for the clinical treatment of UC, their application is often limited by unsatisfactory long-term effects, side effects, and high treatment costs. Therefore, there is an urgent need for the development of effective drugs with fewer side effects. In this study, we found that the extracellular vesicles extracted and purified from rhizomes of Kaempferia galanga L. (KGEVs) exhibit promising therapeutic effects in treating UC disease. With an average diameter of 133.8 nm, KGEVs are rich in functional components, including lipids, proteins, and pharmacologically and immunologically active molecules. In vivo experiments revealed that KG</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T15:53:32.729Z</modification><creation>2026-06-02T03:09:22.798Z</creation></dates><accession>S-EPMC12798018</accession><cross_references><pubmed>41350681</pubmed><doi>10.1186/s12951-025-03897-8</doi></cross_references></HashMap>